The blood–brain barrier (BBB) is a barrier that separates the blood from the brain tissue and
possesses unique characteristics that make the delivery of drugs to the brain a great …

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) comprise a
category of versatile drug delivery systems that have been used in the biomedical field for> …

Drug delivery to central nervous system (CNS) diseases is very challenging since the
presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier …

In this modern era, with the help of various advanced technologies, medical science has
overcome most of the health-related issues successfully. Though, some diseases still remain …

Alzheimer's disease (AD) is a progressive deterioration of brain function, initially
characterized by cognitive deficits, with loss of recent memory and language ability …

Intravenously injected nanoparticulate drug carriers provide a wide range of unique
opportunities for site-specific targeting of therapeutic agents to many areas within the …

Alzheimer's disease (AD) will affect around 115 million people worldwide by the year 2050.
It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and …

Nanoparticles (NPs) are materials with overall dimensions in the nanoscale range. They
have unique physicochemical properties, and have emerged as important players in current …

The blood-brain barrier (BBB) restricts the access of therapeutic agents to the brain,
complicating the treatment of neurological diseases, such as Alzheimer's disease (AD) …

Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are
caused by neuronal degradations, dysfunctions, or death. Alzheimer's disease, Parkinson's …